In an era of health reform, diagnostic technologies that focus on prevention and test the viability of expensive treatment options are becoming increasingly valuable to health providers, payers, and patients. Historically, investment in this sector has not seen the vigor demonstrated with medical devices or biotech innovations. However, in today’s environment, diagnostics are becoming attractive opportunities for companies looking for collaborations or acquisitions as well as investors looking for cutting-edge technologies, all creating a robust industry on the brink of breaking through to the mainstream.
In this presentation, panelists will:
- Provide insight on the diagnostic industry on a local and national level
- Discuss key elements that are reviewed when assessing start-up opportunities
- Discuss where opportunities exist for maximizing profits
- Provide new strategies for raising funds in this dynamic marketplace
Panelist:
Ronald S. Eppen, Partner, Foley & Lardner LLP
Lucy Lu, Vice President of Business Development, Crescendo Bioscience
Natasha Paul, Ph.D., Scientific Investigator, TriLink Biotechnologies, Inc.
Jon Vance, Director, Avondale Partners, LLC
Related Insights
June 9, 2025
Labor & Employment Law Perspectives
Supreme Court Clarifies Discrimination Test in Unanimous Decision
On June 5, 2025, the U.S. Supreme Court in Ames v. Ohio Department of Youth Services unanimously ruled that a plaintiff bringing an…
June 9, 2025
Labor & Employment Law Perspectives
Pride and Prejudice: Federal Court in Texas Vacates Portions of the EEOC’s Workplace Guidance Protecting LGBTQ+ Employees
On May 15, 2025, the U.S. District Court for the Northern District of Texas issued a significant ruling in State of Texas v. Equal…
June 9, 2025
Foley Viewpoints
New Disclosure Requirements for Florida Resorts and Food Establishments
Described as a law to make it easier to remove hotel guests who have not paid their bills, Florida Bill SB 606 (“the Bill”) includes…